34 results on '"Galldiks, N."'
Search Results
2. P01.02.B Case Report: Disruption of Resting-State Networks and Cognitive Deficits After Whole Brain Irradiation for Singular Brain Metastasis
3. P11.53.B Efficacy and tolerability of regorafenib in pretreated patients with progressive CNS grade 3 or 4 gliomas
4. PL01.6.A Radiomics outperforms semantic features for prediction of response to stereotactic radiosurgery in brain metastases
5. P15.05.A Prediction of response to lomustine-based chemotherapy in glioma patients at relapse using MRI and FET PET
6. KS05.5.A Alterations in white matter fiber density associated with structural MRI and metabolic PET lesions following multimodal therapy in glioma patients
7. P17.19.B Incidence of treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma treated with cilengitide (EORTC 26071 - CENTRIC study): interim analysis
8. P13.03.A Radiomics for the non-invasive assessment of the PDL-1 expression in patients with non-small cell lung cancer brain metastases
9. KS02.7.A Impact of FET PET on multidisciplinary neurooncological tumor board decisions in patients with brain tumors
10. P14.06 Radiomics for the non-invasive determination of the BRAF mutational status in patients with melanoma brain metastases
11. P14.41 Cost-effectiveness of FET PET for early treatment response assessment in glioma patients following adjuvant temozolomide chemotherapy
12. P14.79 Differentiation of treatment-related changes from tumor progression following brachytherapy in patients with WHO II and III gliomas using FET PET
13. OS03.3.A Characterization of long-term metabolic changes of irradiated brain metastases using serial dynamic FET PET imaging
14. P14.32 Spatial discrepancies between FET PET and conventional MRI in patients with newly diagnosed glioblastoma
15. OS9.6 Diagnosis of pseudoprogression using FET PET radiomics
16. P14.29 Prediction of overall survival in patients with malignant glioma using dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine PET
17. P04.07 Correlation of 18F-fluorethyl-L-tyrosine (18F-FET) uptake in positron emission tomography (PET) and MRI growth rate in low-grade glioma
18. P14.17 Differentiation of treatment-related changes from tumor progression: A direct comparison between dynamic FET PET and ADC values obtained from DWI MRI
19. P14.18 Prognostic value of serial dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine PET in patients with non-resectable malignant glioma undergoing chemoradiation
20. P01.014 Spatial correlation of FET uptake and MRI contrast enhancement in newly diagnosed glioblastoma patients prior to treatment
21. P05.11 Combined FET PET/MRI radiomics for the differentiation of radiation injury from recurrent brain metastasis
22. P09.26 FET PET radiomics - diagnosis of pseudoprogression in glioblastoma patients based on textural features
23. P10.17 Predicting isocitrate dehydrogenase genotype in malignant glioma using FET PET radiomics
24. The use of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma
25. NI-19 * THE USE OF DYNAMIC O-(2-[18F]fluoroethyl)-L-TYROSINE-PET IN THE CLINICAL EVALUATION OF BRAIN TUMORS IN CHILDREN AND ADOLESCENTS
26. NI-29 * DIAGNOSIS OF PSEUDOPROGRESSION IN PATIENTS WITH GLIOBLASTOMA USING AMINO ACID PET
27. NI-37 * INCREASED CEREBRAL AMINO ACID UPTAKE DURING AND AFTER EPILEPTIC DISORDERS MIMICS BRAIN TUMOR IN 18F-FET PET
28. BI-26 * HOW MUCH INSIGHT CAN A STEREOTACTIC BIOPSY DELIVER?
29. P16.10 * DIAGNOSIS OF PSEUDOPROGRESSION IN PATIENTS WITH GLIOBLASTOMA USING AMINO ACID PET
30. P17.76 * LOW-DOSE RATE STEREOTACTIC IODINE-125 BRACHYTHERAPY FOR THE TREATMENT OF INOPERABLE PRIMARY AND RECURRENT GLIOBLASTOMA: SINGLE-CENTER EXPERIENCE WITH 201 CASES
31. P16.17 * F-18-FET PET IMAGING FOR DIAGNOSIS OF LATE PSEUDOPROGRESSION IN PATIENTS WITH HIGH-GRADE GLIOMAS
32. O7.05 * DIFFERENTIATION OF LOCAL RECURRENT BRAIN METASTASIS FROM RADIATION-INDUCED CHANGES USING O-(2-[18F]FLUOROETHYL)-L-TYROSINE PET
33. Stereotactic iodine-125 brachytherapy for the treatment of WHO grades II and III gliomas located in the central sulcus region
34. Reply to "[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.